4r5y - Revision history

OCA at 12:50, 1 March 2024

OCA — Fri, 01 Mar 2024 12:50:33 GMT

←Older revision		Revision as of 12:50, 1 March 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4r5y]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4R5Y OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4R5Y FirstGlance]. <br>		<table><tr><td colspan='2'>[[4r5y]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4R5Y OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4R5Y FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=3K3:5-({(1R,1AS,6BR)-1-[5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOL-2-YL]-1A,6B-DIHYDRO-1H-CYCLOPROPA[B][1]BENZOFURAN-5-YL}OXY)-3,4-DIHYDRO-1,8-NAPHTHYRIDIN-2(1H)-ONE'>3K3</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 3.5Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=3K3:5-({(1R,1AS,6BR)-1-[5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOL-2-YL]-1A,6B-DIHYDRO-1H-CYCLOPROPA[B][1]BENZOFURAN-5-YL}OXY)-3,4-DIHYDRO-1,8-NAPHTHYRIDIN-2(1H)-ONE'>3K3</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4r5y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4r5y OCA], [https://pdbe.org/4r5y PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4r5y RCSB], [https://www.ebi.ac.uk/pdbsum/4r5y PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4r5y ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4r5y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4r5y OCA], [https://pdbe.org/4r5y PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4r5y RCSB], [https://www.ebi.ac.uk/pdbsum/4r5y PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4r5y ProSAT]</span></td></tr>
	</table>		</table>
Line 11:		Line 12:
	== Function ==		== Function ==
	[https://www.uniprot.org/uniprot/BRAF_HUMAN BRAF_HUMAN] Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron.		[https://www.uniprot.org/uniprot/BRAF_HUMAN BRAF_HUMAN] Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron.
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAF(V600E) metastatic melanoma, their clinical efficacy in BRAF(V600E) colorectal cancer is far less impressive. Prior studies suggested that feedback activation of EGFR and MAPK signaling upon BRAF inhibition might contribute to the relative unresponsiveness of colorectal cancer to the first-generation BRAF inhibitors. Here, we report characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clinical investigation. In vitro, BGB-283 potently inhibits BRAF(V600E)-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAF(V600E) and EGFR mutation/amplification. In BRAF(V600E) colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation. In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRAF(V600E) mutation. These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAF(V600E) mutation.
-
-	BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.,Tang Z, Yuan X, Du R, Cheung SH, Zhang G, Wei J, Zhao Y, Feng Y, Peng H, Zhang Y, Du Y, Hu X, Gong W, Liu Y, Gao Y, Liu Y, Hao R, Li S, Wang S, Ji J, Zhang L, Li S, Sutton D, Wei M, Zhou C, Wang L, Luo L Mol Cancer Ther. 2015 Oct;14(10):2187-97. doi: 10.1158/1535-7163.MCT-15-0262., Epub 2015 Jul 24. PMID:26208524<ref>PMID:26208524</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 4r5y" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==

OCA at 06:41, 2 March 2023

OCA — Thu, 02 Mar 2023 06:41:35 GMT

←Older revision		Revision as of 06:41, 2 March 2023
Line 1:		Line 1:

	==The complex structure of Braf V600E kinase domain with a novel Braf inhibitor==		==The complex structure of Braf V600E kinase domain with a novel Braf inhibitor==
-	<StructureSection load='4r5y' size='340' side='right' caption='[[4r5y]], [[Resolution\|resolution]] 3.50Å' scene=''>	+	<StructureSection load='4r5y' size='340' side='right'caption='[[4r5y]], [[Resolution\|resolution]] 3.50Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4r5y]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4R5Y OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4R5Y FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4r5y]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4R5Y OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4R5Y FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3K3:5-({(1R,1AS,6BR)-1-[5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOL-2-YL]-1A,6B-DIHYDRO-1H-CYCLOPROPA[B][1]BENZOFURAN-5-YL}OXY)-3,4-DIHYDRO-1,8-NAPHTHYRIDIN-2(1H)-ONE'>3K3</scene~~></td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=3K3:5-({(1R,1AS,6BR)-1-[5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOL-2-YL]-1A,6B-DIHYDRO-1H-CYCLOPROPA[B][1]BENZOFURAN-5-YL}OXY)-3,4-DIHYDRO-1,8-NAPHTHYRIDIN-2(1H)-ONE'>3K3</scene></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">BRAF, BRAF1, RAFB1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4r5y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4r5y OCA], [https://pdbe.org/4r5y PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4r5y RCSB], [https://www.ebi.ac.uk/pdbsum/4r5y PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4r5y ProSAT]</span></td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4r5y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4r5y OCA], [~~http~~://pdbe.org/4r5y PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4r5y RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4r5y PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4r5y ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/BRAF_HUMAN BRAF_HUMAN]] Note=Defects in BRAF are found in a wide range of cancers.<ref>PMID:18974108</ref> Defects in BRAF may be a cause of colorectal cancer (CRC) [MIM:[~~http~~://omim.org/entry/114500 114500]].<ref>PMID:18974108</ref> Defects in BRAF are involved in lung cancer (LNCR) [MIM:[~~http~~://omim.org/entry/211980 211980]]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.<ref>PMID:18974108</ref> <ref>PMID:12460919</ref> Defects in BRAF are involved in non-Hodgkin lymphoma (NHL) [MIM:[~~http~~://omim.org/entry/605027 605027]]. NHL is a cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.<ref>PMID:18974108</ref> <ref>PMID:14612909</ref> Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:[~~http~~://omim.org/entry/115150 115150]]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.<ref>PMID:18974108</ref> Defects in BRAF are the cause of Noonan syndrome type 7 (NS7) [MIM:[~~http~~://omim.org/entry/613706 613706]]. Noonan syndrome is a disorder characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits.<ref>PMID:18974108</ref> <ref>PMID:19206169</ref> Defects in BRAF are the cause of LEOPARD syndrome type 3 (LEOPARD3) [MIM:[~~http~~://omim.org/entry/613707 613707]]. LEOPARD3 is a disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.<ref>PMID:18974108</ref> <ref>PMID:19206169</ref> Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation.<ref>PMID:18974108</ref>	+	[https://www.uniprot.org/uniprot/BRAF_HUMAN BRAF_HUMAN] Note=Defects in BRAF are found in a wide range of cancers.<ref>PMID:18974108</ref> Defects in BRAF may be a cause of colorectal cancer (CRC) [MIM:[https://omim.org/entry/114500 114500].<ref>PMID:18974108</ref> Defects in BRAF are involved in lung cancer (LNCR) [MIM:[https://omim.org/entry/211980 211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.<ref>PMID:18974108</ref> <ref>PMID:12460919</ref> Defects in BRAF are involved in non-Hodgkin lymphoma (NHL) [MIM:[https://omim.org/entry/605027 605027]. NHL is a cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.<ref>PMID:18974108</ref> <ref>PMID:14612909</ref> Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:[https://omim.org/entry/115150 115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.<ref>PMID:18974108</ref> Defects in BRAF are the cause of Noonan syndrome type 7 (NS7) [MIM:[https://omim.org/entry/613706 613706]. Noonan syndrome is a disorder characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits.<ref>PMID:18974108</ref> <ref>PMID:19206169</ref> Defects in BRAF are the cause of LEOPARD syndrome type 3 (LEOPARD3) [MIM:[https://omim.org/entry/613707 613707]. LEOPARD3 is a disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.<ref>PMID:18974108</ref> <ref>PMID:19206169</ref> Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation.<ref>PMID:18974108</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/BRAF_HUMAN BRAF_HUMAN]] Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron.	+	[https://www.uniprot.org/uniprot/BRAF_HUMAN BRAF_HUMAN] Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 22:		Line 20:
	</div>		</div>
	<div class="pdbe-citations 4r5y" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4r5y" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Serine/threonine protein kinase 3D structures\|Serine/threonine protein kinase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
-	[[Category: ~~Non-specific serine/threonine protein kinase~~]]	+	[[Category: Large Structures]]
-	[[Category: Feng, Y]]	+	[[Category: Feng Y]]
-	[[Category: Liu, Y]]	+	[[Category: Liu Y]]
-	[[Category: Peng, H]]	+	[[Category: Peng H]]
-	[[Category: Wei, M]]	+	[[Category: Wei M]]
-	[[Category: Zhang, Y]]	+	[[Category: Zhang Y]]
-	~~[[Category: Kinase]]~~	+
-	~~[[Category: Signal transduction]]~~	+
-	~~[[Category: Transferase-transferase inhibitor complex~~]]	+

OCA at 09:01, 22 November 2017

OCA — Wed, 22 Nov 2017 09:01:51 GMT

←Older revision		Revision as of 09:01, 22 November 2017
Line 3:		Line 3:
	<StructureSection load='4r5y' size='340' side='right' caption='[[4r5y]], [[Resolution\|resolution]] 3.50Å' scene=''>		<StructureSection load='4r5y' size='340' side='right' caption='[[4r5y]], [[Resolution\|resolution]] 3.50Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4r5y]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4R5Y OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4R5Y FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4r5y]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4R5Y OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4R5Y FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3K3:5-({(1R,1AS,6BR)-1-[5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOL-2-YL]-1A,6B-DIHYDRO-1H-CYCLOPROPA[B][1]BENZOFURAN-5-YL}OXY)-3,4-DIHYDRO-1,8-NAPHTHYRIDIN-2(1H)-ONE'>3K3</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3K3:5-({(1R,1AS,6BR)-1-[5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOL-2-YL]-1A,6B-DIHYDRO-1H-CYCLOPROPA[B][1]BENZOFURAN-5-YL}OXY)-3,4-DIHYDRO-1,8-NAPHTHYRIDIN-2(1H)-ONE'>3K3</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">BRAF, BRAF1, RAFB1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4r5y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4r5y OCA], [http://pdbe.org/4r5y PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4r5y RCSB], [http://www.ebi.ac.uk/pdbsum/4r5y PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4r5y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4r5y OCA], [http://pdbe.org/4r5y PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4r5y RCSB], [http://www.ebi.ac.uk/pdbsum/4r5y PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4r5y ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 25:		Line 26:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Non-specific serine/threonine protein kinase]]		[[Category: Non-specific serine/threonine protein kinase]]
	[[Category: Feng, Y]]		[[Category: Feng, Y]]

OCA at 18:10, 26 February 2016

OCA — Fri, 26 Feb 2016 18:10:03 GMT

←Older revision		Revision as of 18:10, 26 February 2016
Line 1:		Line 1:
-	'''Unreleased structure'''

-	The ~~entry~~ 4r5y is ~~ON HOLD~~ ~~until Feb 24 2017~~	+	==The complex structure of Braf V600E kinase domain with a novel Braf inhibitor==
		+	<StructureSection load='4r5y' size='340' side='right' caption='[[4r5y]], [[Resolution\|resolution]] 3.50Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[4r5y]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4R5Y OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4R5Y FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3K3:5-({(1R,1AS,6BR)-1-[5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOL-2-YL]-1A,6B-DIHYDRO-1H-CYCLOPROPA[B][1]BENZOFURAN-5-YL}OXY)-3,4-DIHYDRO-1,8-NAPHTHYRIDIN-2(1H)-ONE'>3K3</scene></td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4r5y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4r5y OCA], [http://pdbe.org/4r5y PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4r5y RCSB], [http://www.ebi.ac.uk/pdbsum/4r5y PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/BRAF_HUMAN BRAF_HUMAN]] Note=Defects in BRAF are found in a wide range of cancers.<ref>PMID:18974108</ref> Defects in BRAF may be a cause of colorectal cancer (CRC) [MIM:[http://omim.org/entry/114500 114500]].<ref>PMID:18974108</ref> Defects in BRAF are involved in lung cancer (LNCR) [MIM:[http://omim.org/entry/211980 211980]]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.<ref>PMID:18974108</ref> <ref>PMID:12460919</ref> Defects in BRAF are involved in non-Hodgkin lymphoma (NHL) [MIM:[http://omim.org/entry/605027 605027]]. NHL is a cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.<ref>PMID:18974108</ref> <ref>PMID:14612909</ref> Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:[http://omim.org/entry/115150 115150]]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.<ref>PMID:18974108</ref> Defects in BRAF are the cause of Noonan syndrome type 7 (NS7) [MIM:[http://omim.org/entry/613706 613706]]. Noonan syndrome is a disorder characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits.<ref>PMID:18974108</ref> <ref>PMID:19206169</ref> Defects in BRAF are the cause of LEOPARD syndrome type 3 (LEOPARD3) [MIM:[http://omim.org/entry/613707 613707]]. LEOPARD3 is a disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.<ref>PMID:18974108</ref> <ref>PMID:19206169</ref> Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation.<ref>PMID:18974108</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/BRAF_HUMAN BRAF_HUMAN]] Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAF(V600E) metastatic melanoma, their clinical efficacy in BRAF(V600E) colorectal cancer is far less impressive. Prior studies suggested that feedback activation of EGFR and MAPK signaling upon BRAF inhibition might contribute to the relative unresponsiveness of colorectal cancer to the first-generation BRAF inhibitors. Here, we report characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clinical investigation. In vitro, BGB-283 potently inhibits BRAF(V600E)-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAF(V600E) and EGFR mutation/amplification. In BRAF(V600E) colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation. In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRAF(V600E) mutation. These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAF(V600E) mutation.

-	~~Authors: Feng~~, Y., ~~Peng~~, H., Zhang, Y., Liu, Y., ~~Wei~~, M.	+	BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.,Tang Z, Yuan X, Du R, Cheung SH, Zhang G, Wei J, Zhao Y, Feng Y, Peng H, Zhang Y, Du Y, Hu X, Gong W, Liu Y, Gao Y, Liu Y, Hao R, Li S, Wang S, Ji J, Zhang L, Li S, Sutton D, Wei M, Zhou C, Wang L, Luo L Mol Cancer Ther. 2015 Oct;14(10):2187-97. doi: 10.1158/1535-7163.MCT-15-0262., Epub 2015 Jul 24. PMID:26208524<ref>PMID:26208524</ref>

-	~~Description: The complex structure of Braf V600E kinase domain with~~ a ~~novel Braf inhibitor~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
-	[[Category: ~~Zhang~~, Y]]	+	<div class="pdbe-citations 4r5y" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Non-specific serine/threonine protein kinase]]
		+	[[Category: Feng, Y]]
	[[Category: Liu, Y]]		[[Category: Liu, Y]]
	[[Category: Peng, H]]		[[Category: Peng, H]]
-	[[Category: Feng, Y]]
	[[Category: Wei, M]]		[[Category: Wei, M]]
		+	[[Category: Zhang, Y]]
		+	[[Category: Kinase]]
		+	[[Category: Signal transduction]]
		+	[[Category: Transferase-transferase inhibitor complex]]

OCA at 09:54, 8 July 2015

OCA — Wed, 08 Jul 2015 09:54:08 GMT

←Older revision		Revision as of 09:54, 8 July 2015
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4r5y is ON HOLD until ~~Paper Publication~~	+	The entry 4r5y is ON HOLD until Feb 24 2017

	Authors: Feng, Y., Peng, H., Zhang, Y., Liu, Y., Wei, M.		Authors: Feng, Y., Peng, H., Zhang, Y., Liu, Y., Wei, M.

OCA at 16:31, 24 December 2014

OCA — Wed, 24 Dec 2014 16:31:08 GMT

←Older revision		Revision as of 16:31, 24 December 2014
Line 6:		Line 6:

	Description: The complex structure of Braf V600E kinase domain with a novel Braf inhibitor		Description: The complex structure of Braf V600E kinase domain with a novel Braf inhibitor
		+	[[Category: Unreleased Structures]]
		+	[[Category: Zhang, Y]]
		+	[[Category: Liu, Y]]
		+	[[Category: Peng, H]]
		+	[[Category: Feng, Y]]
		+	[[Category: Wei, M]]

OCA at 06:27, 8 October 2014

OCA — Wed, 08 Oct 2014 06:27:45 GMT

←Older revision		Revision as of 06:27, 8 October 2014
Line 3:		Line 3:
	The entry 4r5y is ON HOLD until Paper Publication		The entry 4r5y is ON HOLD until Paper Publication

-	Authors: Feng, Y., Peng, H., Zhang, Y., Liu, Y., Wei, M	+	Authors: Feng, Y., Peng, H., Zhang, Y., Liu, Y., Wei, M.

	Description: The complex structure of Braf V600E kinase domain with a novel Braf inhibitor		Description: The complex structure of Braf V600E kinase domain with a novel Braf inhibitor

OCA at 08:23, 24 September 2014

OCA — Wed, 24 Sep 2014 08:23:37 GMT

←Older revision		Revision as of 08:23, 24 September 2014
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4r5y is ON HOLD	+	The entry 4r5y is ON HOLD until Paper Publication

	Authors: Feng, Y., Peng, H., Zhang, Y., Liu, Y., Wei, M		Authors: Feng, Y., Peng, H., Zhang, Y., Liu, Y., Wei, M

	Description: The complex structure of Braf V600E kinase domain with a novel Braf inhibitor		Description: The complex structure of Braf V600E kinase domain with a novel Braf inhibitor

OCA: Protected "4r5y" [edit=sysop:move=sysop]

OCA — Thu, 04 Sep 2014 04:15:48 GMT

Protected "4r5y" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:15, 4 September 2014

OCA: New page: '''Unreleased structure''' The entry 4r5y is ON HOLD Authors: Feng, Y., Peng, H., Zhang, Y., Liu, Y., Wei, M Description: The complex structure of Braf V600E kinase domain with a novel...

OCA — Thu, 04 Sep 2014 04:15:47 GMT

New page: '''Unreleased structure''' The entry 4r5y is ON HOLD Authors: Feng, Y., Peng, H., Zhang, Y., Liu, Y., Wei, M Description: The complex structure of Braf V600E kinase domain with a novel...

New page

'''Unreleased structure'''

The entry 4r5y is ON HOLD

Authors: Feng, Y., Peng, H., Zhang, Y., Liu, Y., Wei, M

Description: The complex structure of Braf V600E kinase domain with a novel Braf inhibitor